Wednesday, February 10, 2010, 7:30am EST - Canadian Markets open in 2 hours.
To create a watchlist or portfolio of shares, Sign-in or Register

Simulations Plus Inc. (SLP)

 On Feb 9: 1.72 USD   0.00 (0.00%)  
MORE ON SLP
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Simulations Plus, Inc. (NCM:SLP) Delayed quote dataEdit
Last Trade: 1.72 USD
Trade Time: Feb 9
Change: 0.00 (0.00%)
Prev Close: 1.72
Open: N/A
Bid: 1.65 x 10000
Ask: N/A
1y Target Est: 2.40
Day's Range: N/A - N/A
52wk Range: 0.79 - 2.05
Volume: 0
Avg Vol (3m): 26,203.2
Market Cap: 26.97M
P/E (ttm): 18.70
EPS (ttm): 0.09
Div & Yield: N/A (N/A%)
Simulations Plus Inc. (SLP)
1d  5d  3m  6m  1y  2y  5y  max 
 Add SLP to Portfolio   Download Data

HEADLINES
• Simulations Plus Launches Biorelevant Solubility Database
Business Wire (Thu, Jan 21)
• SIMULATIONS PLUS INC Financials
EDGAR Online Financials (Wed, Jan 20)
• Simulations Plus Announces Renewed Share Repurchase Program
Business Wire (Wed, Jan 20)
• SIMULATIONS PLUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online (Tue, Jan 19)
• New Star Analyst Rankings for Simulations Plus, Inc.
StarMine (Thu, Jan 14)
• Simulations Plus Reports First Quarter FY2010 Financial Results
Business Wire (Wed, Jan 13)
• SIMULATIONS PLUS INC Files SEC form 10-Q, Quarterly Report
EDGAR Online (Wed, Jan 13)
• Simulations Plus to Present at Biotech Showcase 2010
Business Wire (Tue, Jan 12)
• Simulations Plus Sets Date for 1st Quarter Fiscal Year 2010 Earnings Release and Conference Call
Business Wire (Tue, Jan 12)
• Simulations Plus Appoints John DiBella, M.S. Manager, Marketing and Sales
Business Wire (Wed, Dec 16)
More Headlines for SLP...
ANALYST
EPS Est (next year) (Aug-10) : 0.11
EPS Est (in 2 years) (Aug-11) : 0.13
Avg Rec (current)*: 2.0
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Simulations Plus, Inc. develops and produces software for use in pharmaceutical research and education, as well as provides contract research services to the pharmaceutical industry.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices